ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a potent, selective inhibitor of the transcription factor NRF2, with an IC50 of 1.9 μM in cellular assays. It downregulates NRF2-dependent gene expression in a dose- and time-dependent manner, as shown in A549 non-small cell lung cancer (NSCLC) cells (APExBIO). In vivo, ML385 reduces tumor growth and metastasis in NSCLC mouse models and enhances the efficacy of chemotherapeutics such as carboplatin (Wang et al., 2024). ML385 is also a critical tool for dissecting oxidative stress responses and ferroptosis mechanisms in neuroscience and metabolic disease models. Its well-characterized solubility, stability, and selectivity profiles make it an essential reagent for NRF2 signaling pathway inhibition in translational research.

Biological Rationale

NRF2 (nuclear factor erythroid 2-related factor 2) is a master transcriptional regulator of genes involved in antioxidant defense, detoxification, and multidrug transporter expression (Wang et al., 2024). Aberrant activation of NRF2 has been implicated in cancer cell survival, therapeutic resistance, and the pathogenesis of neurodegenerative and metabolic diseases. In non-small cell lung cancer (NSCLC), NRF2 upregulation contributes to chemoresistance by increasing expression of cytoprotective and efflux genes (CCT241533.com). In the nervous system, NRF2 modulates oxidative stress and ferroptosis, processes linked to cognitive decline in diabetes and neurodegeneration. Targeting NRF2 with selective inhibitors like ML385 enables precise experimental manipulation of these pathways, supporting the development of new therapeutic strategies.

Mechanism of Action of ML385

ML385 is a small molecule that selectively binds to the Neh1 DNA-binding domain of NRF2, blocking its ability to initiate transcription of downstream antioxidant and detoxification genes (APExBIO). This inhibition occurs in a dose-dependent manner, with an IC50 of 1.9 μM reported in cell-based assays. ML385 does not significantly inhibit closely related transcription factors under standard conditions, demonstrating high selectivity. In A549 NSCLC cell lines, ML385 treatment results in decreased expression of canonical NRF2 target genes such as HO-1 and GPX4 (Wang et al., 2024). In vivo, systemic administration of ML385 reduces NRF2 activity in tumor and brain tissues, as evidenced by Western blot and immunohistochemistry analyses.

Evidence & Benchmarks

• ML385 inhibits NRF2-dependent transcriptional activity in A549 NSCLC cells with an IC50 of 1.9 μM under standard culture conditions (APExBIO).
• In NSCLC mouse xenograft models, ML385 administration reduces tumor growth and metastasis, especially when combined with carboplatin chemotherapy (Wang et al., 2024).
• ML385 blocks the neuroprotective effects of artemisinin in T2DM mice by inhibiting NRF2-mediated antioxidant gene upregulation and thereby restores susceptibility to ferroptosis in hippocampal neurons (Wang et al., 2024, Fig. 5).
• ML385 is insoluble in ethanol and water but soluble ≥13.33 mg/mL in DMSO at room temperature; storage at -20°C preserves compound stability (APExBIO).
• Multiple independent studies confirm that ML385 enables specific inhibition of NRF2 signaling without off-target effects on related bZIP transcription factors at recommended concentrations (lb-broth-lennox.com).

This article extends prior coverage (e.g., CCT241533.com) by integrating new in vivo and neurodegeneration data, specifically the role of ML385 in ferroptosis modulation, which was not addressed in earlier cancer-focused reviews.

Applications, Limits & Misconceptions

ML385 is primarily used in the following research contexts:

• Dissection of NRF2 signaling in cancer biology, especially NSCLC.
• Investigation of oxidative stress and ferroptosis in neurodegeneration and metabolic disease models.
• Validation of NRF2 as a therapeutic resistance driver using combination treatments with chemotherapeutics like carboplatin.

For best practices in experimental design, see Scenario-Driven Best Practices for ML385, which details workflow integration and troubleshooting; this article updates those guidelines with new evidence from neuroscience models.

Common Pitfalls or Misconceptions

• ML385 is not effective in cell lines or systems lacking NRF2 overactivation; baseline NRF2 expression must be confirmed before use.
• ML385 is insoluble in water and ethanol; improper solvent use reduces effective dosing.
• Long-term storage of ML385 solutions (especially in DMSO at room temperature) leads to compound degradation and loss of activity.
• ML385 does not inhibit other bZIP family transcription factors at recommended concentrations; activity is NRF2-specific.
• ML385 is not approved for clinical use; it is a research-only reagent.

Workflow Integration & Parameters

ML385 (SKU B8300) should be dissolved in DMSO to a concentration of ≥13.33 mg/mL before dilution into cell culture or animal dosing buffers (ML385 product page). Solutions should be freshly prepared or stored at -20°C for short periods. For cell-based assays, typical working concentrations range from 0.5 to 10 μM, with validation in the specific system recommended. In animal studies, dosing regimens are model-dependent; published NSCLC protocols use intraperitoneal administration at 20–40 mg/kg. For detailed scenario-driven protocols and compatibility data, refer to Scenario-Driven Best Practices; our current article incorporates recent evidence from diabetes/ferroptosis models not covered in earlier work.

For advanced applications in combinatorial cancer therapy and neurodegenerative disease, see Advanced NRF2 Inhibition Strategies in Cancer and Neurodegeneration, which is complemented here by updated mechanism data and evidence from new in vivo models.

Conclusion & Outlook

ML385, available from APExBIO, is a validated, selective NRF2 inhibitor enabling precise inhibition of NRF2 signaling pathways in cancer, metabolic, and neurodegenerative research. Its robust selectivity, well-documented solubility/stability, and efficacy in both cellular and animal models make it an essential reagent for exploring oxidative stress modulation and therapeutic resistance mechanisms. Ongoing studies will further elucidate ML385’s potential in combinatorial therapies and clarify its role in regulating ferroptosis beyond current cancer paradigms (Wang et al., 2024).